PAVmed (PAVM) EBIAT (2021 - 2025)
PAVmed (PAVM) has 5 years of EBIAT data on record, last reported at -$5.0 million in Q3 2025.
- For Q3 2025, EBIAT changed N/A year-over-year to -$5.0 million; the TTM value through Sep 2025 reached $3.1 million, changed N/A, while the annual FY2024 figure was $39.8 million, 150.2% up from the prior year.
- EBIAT reached -$5.0 million in Q3 2025 per PAVM's latest filing, up from -$11.9 million in the prior quarter.
- Across five years, EBIAT topped out at $18.6 million in Q1 2025 and bottomed at -$29.1 million in Q4 2023.
- Average EBIAT over 5 years is -$14.7 million, with a median of -$15.1 million recorded in 2024.
- Peak YoY movement for EBIAT: plummeted 152.43% in 2022, then soared 222.42% in 2025.
- A 5-year view of EBIAT shows it stood at -$17.2 million in 2021, then plummeted by 64.82% to -$28.4 million in 2022, then dropped by 2.63% to -$29.1 million in 2023, then soared by 104.91% to $1.4 million in 2024, then plummeted by 452.06% to -$5.0 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$5.0 million in Q3 2025, -$11.9 million in Q2 2025, and $18.6 million in Q1 2025.